Second, our findings point to the diffuse expression of TOPK as an adverse prognostic factor in patients with sporadic CRC with a KRAS or BRAF mutation and in metastatic patients with SD or PR after treatment with anti-EGFR-based regimens. This evidence concerns the gene KRAS and colorectal carcinoma.